Respiratory syncytial virus replication inhibitors

Details Respiratory syncytial virus replication inhibitors Respiratory syncytial virus replication inhibitors

2007-02-06

2007-02-06

Habte, Kahsay (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C514S252030, C514S252060, C514S252110, C514S252140, C514S252190, C514S256000, C514S316000, C514S318000, C514S320000, C514S322000, C514S364000, C514S365000, C514S372000, C514S374000, C514S339000, C514S378000, C514S394000, C544S295000, C544S238000, C544S364000, C544S357000, C544S370000, C546S193000, C546S199000, C548S306100, C548S304400

Reexamination Certificate

active

11144126

ABSTRACT:
This invention concerns the use of compounds of formula (I) wherein -a1=a2-a3=a4- is a radical of for CH═CH—, —N═CH—CH═CH—, —CH═N—CH═CH—, —CH═CH—N═CH—, —CH═CH—CH═N— wherein each hydrogen atom may optionally be substituted; Q is a radical of formulas (b-1), (b-2), (b-3), (b-4), (b-5), (b-6), (b-7), (b-8), G is a direct bond or C1-10alkanediyl; R1is an optionally substituted monocyclic heterocycle; for the manufacture of a medicament for the treatment of viral infections, in particular RSV infections. Certain compounds of formula (I) are new.

REFERENCES:
patent: 4634704 (1987-01-01), Janssens et al.
patent: 4695569 (1987-09-01), Janssens et al.
patent: 4988689 (1991-01-01), Janssens et al.
patent: 5360807 (1994-11-01), Janssens et al.
patent: 5922737 (1999-07-01), Maynard et al.
patent: 5998439 (1999-12-01), Maynard et al.
patent: 6747028 (2004-06-01), Janssens et al.
patent: 6924287 (2005-08-01), Janssens et al.
patent: 0 005 318 (1979-11-01), None
patent: 0 099 139 (1984-01-01), None
patent: 0 144 101 (1985-06-01), None
patent: 0 145 037 (1985-06-01), None
patent: 0 151 824 (1985-08-01), None
patent: 0 151 826 (1985-08-01), None
patent: 0 232 937 (1987-08-01), None
patent: 0 295 742 (1988-12-01), None
patent: 0 297 661 (1989-01-01), None
patent: 0 307 014 (1989-03-01), None
patent: 0 393 738 (1990-10-01), None
patent: 0 747 363 (1996-12-01), None
patent: 0 058 146 (2002-08-01), None
patent: WO 92/01687 (1992-02-01), None
patent: WO 92/01697 (1992-02-01), None
patent: WO 98/10764 (1998-03-01), None
patent: WO 98/31363 (1998-07-01), None
patent: WO 98/55120 (1998-12-01), None
Akula, M. R. et al., “An Improved Synthesis of 3-Phenyl-and 3-Methoxyquinaldine,”Org. Prep. Proced. Int.,1991, 23, pp. 386-387.
Bennett, et al.,Cecil Textbook of Medicine,20thEdition, vol. 2.
Ceré, V. et al., “Catalytic Hydrogenation of Benzo[2.1.3]Oxadiazoles,”Tetrahedron,1972, 28, 3271-3276.
Chiba, T. et al., “Inhibitory Effect of Pyridobenzazoles on Virus Replication in vitro,”Biol Pharm Bull,1995, 18(8), 1081-1083.
Goodman and Gilman, “Biotransformation of Drugs,” inThe Pharmacological Basis of Therapeutics,8thed., McGraw-Hill, Int. Ed. 1992, 13-15.
Greene, T. et al.,Protective Groups in Organic Synthesis,John Wiley & Sons Inc., 1991, Chapter 7.
Lindström, S. et al., “Synthesis of the Mutagenic 2-Amino-1,6-Dimethyl-Imidazo[4,5-b]Pyridine (1,6-DMIP) and Five of Its Isomers,”Heterocycles,1994, 38(3), 529-540.
Richardson, Jr. et al. “Study of the Synthesis and Chemistry of the 5,6-Dihydroimidazo[ij]quinoline Series,”J. Org. Chem.,1960, 25, 1138-1147.
Tidwell, R. et al., “Aromatic Amidines: Comparison of Their Ability to Block Respiratory Syncytial Virus Induced Cell Fusino and to Inhibit Plasmin, Urokinase, Thrombin, and Trypsin,”J Med Chem,1983, 26, 294-298.
Wyde et al., “CL387626 exhibits marked and unusual antiviral activity against respiratory syncytial virus in tissue culture and in cotton rats,”Antivirus Research,1998, 38, 31-42.

Affiliated with

Also associated with

Rating

Respiratory syncytial virus replication inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Respiratory syncytial virus replication inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Respiratory syncytial virus replication inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3893325